Study S000817

Tirzepatide for Individuals With Comorbid Obesity and Methamphetamine Use Disorder

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06745128
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 35
Start: 2025-02-03
Primary completion: 2026-02-12
Lead sponsor: University of Texas Southwestern Medical Center
Conditions: Obesity; Methamphetamine Use Disorder
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Effect of tirzepatide on self-reported use of methamphetamine [36 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009025	Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. Lähteenvuo M, JAMA psychiatry	2025	Nonrandomized study	PMID 39535805 DOI	registry reference BACKGROUND:39535805
R0012433	GLP-1R agonist medications for addiction treatment. Volkow ND, Addiction (Abingdon, England)	2025	Commentary	PMID 39049203 DOI	registry reference BACKGROUND:39049203
R0006728	Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Tan B, International journal of obesity (2005)	2023	Systematic review	PMID 37253796 DOI	registry reference BACKGROUND:37253796